Stockscreener 앱 받기
3.15
2.17%
-0.07
Acelyrin Inc 주식(SLRN)의 최신 뉴스
Fmr LLC Sells 4,596,424 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Fmr LLC - MarketBeat
Charles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
SLRN stock touches 52-week low at $3.18 amid market challenges - Investing.com Australia
Acelyrin (NASDAQ:SLRN) Earns “Neutral” Rating from HC Wainwright - Defense World
Acelyrin stock drops as izokibep trial fails to meet primary endpoint - MSN
Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data - BioSpace
Acelyrin's (SLRN) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
Acelyrin shares retain neutral rating despite trial setback By Investing.com - Investing.com UK
Acelyrin price target lowered to $13 from $15 at Wells Fargo - TipRanks
Point72 Asset Management L.P. Has $1.23 Million Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin shares tumble after decision to halt izokibep development on failing trial - Seeking Alpha
Acelyrin Shares Fall After Halting Development of Eye Disease Treatment - MarketWatch
Acelyrin Finance Chief Gil Labrucherie to Exit - MarketWatch
Acelyrin announces izokibep trial did not meet primary endpoint - TipRanks
ACELYRIN Faces CFO Resignation and Trial Setback - TipRanks
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis - The Manila Times
Acelyrin: Abandoned Programs Do Not Give Confidence (NASDAQ:SLRN) - Seeking Alpha
Polar Asset Management Partners Inc. Sells 150,700 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Jacobs Levy Equity Management Inc. Sells 153,465 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acuta Capital Partners LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.50 Consensus Price Target from Analysts - MarketBeat
HC Wainwright Issues Positive Estimate for Acelyrin Earnings - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Q3 2024 Earnings Call Transcript - Insider Monkey
TD Cowen maintains Buy rating on Acelyrin shares By Investing.com - Investing.com Canada
Acelyrin discloses ValenzaBio acquisition financials - Investing.com India
TD Cowen maintains Buy rating on Acelyrin shares - Investing.com
T. Rowe Price Investment Management, Inc. Reduces Stake in Acely - GuruFocus.com
Earnings call: Acelyrin focuses on TED treatment, eyes Phase 3 trials - Investing.com
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ... By GuruFocus - Investing.com Canada
ACELYRIN, INC. Advances Key Drug Developments - TipRanks
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - The Manila Times
ACELYRIN Reports $562M Cash Position, Advances Key Clinical Trials Amid Pipeline Focus | SLRN Stock News - StockTitan
(SLRN) Investment Analysis and Advice - Stock Traders Daily
Acelyrin (SLRN) Set to Announce Earnings on Wednesday - MarketBeat
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 - The Manila Times
ACELYRIN Sets Q3 2024 Earnings Call: Immunology Pipeline Updates Coming Nov 13 | SLRN Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Acelyrin Inc Shares - GuruFocus.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
2.88%
2.65%
자본화:
|
볼륨(24시간):